"We are proud to present this partnership which has allowed us to introduce a new and improved Chromogranin A kit manufactured by Euro Diagnostica to our customers. The CgAnalyze Kit has an excellent correlation to the previous Dako Chromogranin A ELISA kit and the assay procedures are very similar which enables a smooth and fast transition between the kits," says Simon Østergaard, General Manager, Head of Reagent Partnership Division, part of Agilent’s Genomics and Diagnostics Business.
"Dako is the perfect partner for us," says Else Beth Trautner, CEO of Euro Diagnostica. "Chromogranin A is a key marker for patients suffering from neuroendocrine tumors (NETs) and our easy-to-use assay is highly appreciated by the end-users. With Dako´s solid expertise of biomarkers in the oncology field, combined with global presence, we are confident that our collaboration will be successful".
The CgA kit is an enzyme-linked immunosorbent assay (ELISA) for detection and quantitation of chromogranin A in human plasma and serum. The results of the assay may be used as an aid in the diagnosis of chromogranin A secreting neuroendocrine tumours (NETs), such as phaeochromocytomas and carcinoids.
Please visit this product page for further information on NEOLISA™ Chromogranin A.
Formed in 1992 in Malmö, Sweden, Euro Diagnostica AB is a full service diagnostic solutions company, as well as a developer and manufacturer of high quality assays. Throughout the past twenty years, their world class scientists have been the first to develop and produce top quality ELISA kits for ANCA, anti-CCP, Complement and Chromogranin A assays which are used throughout the world. Euro Diagnostica AB combines a long tradition in R&D with a commitment to quality. Their goal is to constantly develop solutions to aid clinicians in diagnosis, prognosis, monitoring and treatment of autoimmune and related diseases.
Agilent Technologies Inc. (NYSE: A) is the world's premier measurement company and a technology leader in chemical analysis, life sciences, diagnostics, electronics and communications. The company's 20,600 employees serve customers in more than 100 countries. Agilent had revenues of $6.8 billion in fiscal 2013. Agilent acquired Dako in 2012, a well-known provider of reagents, instruments, software and expertise to make accurate diagnoses and determine the most effective treatment for cancer patients. Information about Agilent is available at www.agilent.com and information about Dako products is available at www.dako.com.
On Sept. 19, 2013, Agilent announced plans to separate into two publicly traded companies through a tax-free spinoff of its electronic measurement business. The new company is named Keysight Technologies, Inc. The separation is expected to be completed in early November 2014.« Back